Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0% by supplementary Gla‐100 therapy while sex and BMI were also useful indicators. However, age and C‐peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin (Diabetes, Obesity and Metabolism)
Diabetes News
Category: Treatment
Sliding scale insulin for non‐critically ill hospitalised adults with diabetes mellitus
Based on low‐ to very low‐certainty evidence, our results for non‐critically ill hospitalised adults with diabetes mellitus in the medical and surgical in‐hospital setting showed that a basal‐bolus insulin strategy that applied higher total daily doses of insulin than the sliding scale insulin regimen might result in better short‐term glycaemic control but might also cause an increase in severe hypoglycaemic episodes (Cochrane Systematic Review)
Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes
We concluded that recovery of the AIR could be obtained in T2DM patients of varying disease duration by short-term intensive insulin therapy and it could be conveniently estimated using posttreatment fasting plasma glucose and other fasting indicators (Journal of Diabetes Research)
Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial
Compared with CPT, IPT reduced HbA 1c in patients with type 2 diabetes and moderate-to-severe periodontitis after 12 months. These results suggest that routine oral health assessment and treatment of periodontitis could be important for effective management of type 2 diabetes (The Lancet Diabetes & Endocrinology)
A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
In conclusion, short-term intensive therapy with basal insulin plus OHAs showed comparable benefits to CSII in terms of overall glycemic control and improvement in β-cell function in newly diagnosed patients with type 2 diabetes mellitus and is a possible option for treating newly diagnosed patients with type 2 diabetes (Journal of Diabetes Research)
Effect of Intensive Glycemic Control on Risk of Lower Extremity Amputation
In type 2 diabetics, IGC was associated with a reduction in the risk for LEA. After 3.7 years of IGC there was an enduring protective effect against LEA. Improved glycemic control was a strong predictor of decreased risk for subsequent LEA. This study suggests that tight glycemic control, even over a short time period, has potential to reduce risk of limb loss (Journal of the American College of Surgeons)
Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes
Apart from blood pressure outcomes, there was no evidence that intensive interventions improve or worsen HbA1c, total cholesterol, LDL, triglycerides, urinary albumin excretion rate, risk of cardiovascular or mortality outcomes in people with type 2 diabetes and microalbuminuria (Diabetes Research and Clinical Practice)
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Hybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes (The Lancet)
Artificial Pancreas or Novel Beta-Cell Replacement Therapies: a Race for Optimal Glycemic Control?
Closed loop insulin delivery devices are promising treatment strategies and are likely to be used in clinical practice in the short term. But this approach will always suffer from delays in glucose measurement and insulin action preventing it from normalizing glycemic control. In the long term, stem cell-derived beta cell transplantation may be able to achieve this, but wide implementation in clinical practice is still far away (Current Diabetes Reports)
Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis
Metabolic diseases are becoming the first noticeable disorder which threatens the health and longevity of human. Vaccines are powerful tools in this battle if used properly (Journal of Diabetes Research)
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Restricting therapy for T1DM to insulin replacement is perhaps an over-simplistic approach, and we focus in this work on reviewing the role of adjuvant therapy in this population (Diabetes Therapy)
Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes
Earlier treatment intensification is associated with shorter time to subsequent glycemic control, independent of whether patients initiate first-line treatment with metformin or a sulfonylurea (Diabetes Care)
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study)
Among patients with newly diagnosed diabetes and 10 years of survival, HbA1c levels ≥6.5% (≥48 mmol/mol) for the 1st year after diagnosis were associated with worse outcomes. Immediate, intensive treatment for newly diagnosed patients may be necessary to avoid irremediable long-term risk for diabetic complications and mortality (Diabetes Care)
Real‐World outcomes of insulin pump compared to injection therapy in a population based sample of children with type 1 diabetes
Patients using insulin pump therapy had a better long‐term glycemic control relative to the matched injection therapy cohort. Large population‐based cohort studies using real‐world data provide a valuable perspective on evaluation of new technologies in children with T1D (Pediatric Diabetes)
Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care
Among inpatients with type 2 diabetes receiving noncritical care, the use of an automated, closed-loop insulin-delivery system resulted in significantly better glycemic control than conventional subcutaneous insulin therapy, without a higher risk of hypoglycemia (NEJM)
Practical guidance for treatment of patients with diabetes using flash glucose monitoring: a pilot study
Recognition of the characteristic correlation patterns between SG and SMBG values is indispensable for certified diabetes educators to provide appropriate treatment guidance to patients with diabetes (Diabetology & Metabolic Syndrome)
Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care
Among inpatients with type 2 diabetes receiving noncritical care, the use of an automated, closed-loop insulin-delivery system resulted in significantly better glycemic control than conventional subcutaneous insulin therapy, without a higher risk of hypoglycemia (NEJM)
For Patients With Type 2 Diabetes, What’s the Best Target Hemoglobin A1C?
The ACP set its target higher than recommended by other prominent health groups. The American Diabetes Association (ADA) generally recommends an HbA1C goal of less than 7%, while the American Association of Clinical Endocrinologists (AACE) advises even tighter control of 6.5% or lower if it can be achieved safely (JAMA)
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis
Neither the rate of administration nor the sodium chloride content of intravenous fluids significantly influenced neurologic outcomes in children with diabetic ketoacidosis (NEJM)
The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II
These real-life data show that treatment intensification, including insulin initiation, does not impact adversely on patient well-being in community-based type 2 diabetes (Diabetes Research and Clinical Practice)
- 1
- 2
- 3
- …
- 19
- Next Page »
Glycosmedia is also available as an App: